miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2

详细信息    查看全文

• 作者：Jing Zhou^a ; ¹ ; ^{zhougjing9888@163.com} ; Ye Tian^b ; ¹ ; ^{tianye2010077@163.com} ; Juan Li^a ; ¹ ; ^{402310848@163.com} ; Binbin Lu^a ; ^{lubin1976@163.com} ; Ming Sun^c ; ^{422825636@qq.com} ; Yanfen Zou^d ; ^{569111165@qq.com} ; Rong Kong^c ; ^{31815857@qq.com} ; Yanhong Luo^e ; ^{252376737@qq.com} ; Yongguo Shi^a ; ^{12071018@qq.com} ; Keming Wang^a ; ^{Tianyr1@163.com} ; Guozhong Ji^a ; ^{252376737@qq.com}
• 关键词：miR-206 ; CyclinD2 ; Breast cancer ; Target
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2013
• 出版时间：5 April, 2013
• 年：2013
• 卷：433
• 期：2
• 页码：207-212
• 全文大小：654 K

文摘

MicroRNAs act as important gene regulators in human genomes, and their aberrant expression is linked to many malignancies. Aberrant expression of miR-206 has been frequently reported in cancer studies; however, the role and mechanism of its function in breast cancer remains unclear. Quantitative real-time PCR was performed to detect the relative expression levels of miR-206 in breast cancer and normal breast tissues. Lower expression of miR-206 in breast cancer tissues was associated with larger tumour size and a more advanced clinical stage. Further in vitro observations showed that the enforced expression of miR-206 in MCF-7 breast cancer cells inhibited cell growth by blocking the G1/S transition and suppressed cell proliferation and colony formation, implying that miR-206 functions as a tumour suppressor in the progression of breast cancer. Interestingly, Luciferase assays first revealed that miR-206 inhibited cyclinD2 expression by targeting two binding sites in the 3¡ä-untranslated region of cyclinD2 mRNA. qRT-PCR and Western blot assays verified that miR-206 reduced cyclinD2 expression at both the mRNA and protein levels. A reverse correlation between miR-206 and cyclinD2 expression was noted in breast cancer tissues. Altogether, our results identify a crucial tumour suppressive role of miR-206 in the progression of breast cancer, at least partly via up-regulation of the expression of cyclinD2, and suggest that miR-206 might be a candidate prognostic predictor or an anticancer therapeutic target for breast cancer patients.